1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Medical specialties
ACRO Biomedical Co., Ltd.

ACRO Biomedical Co., Ltd.

TTPEX:6748
185.00
TWD
-6.00
(-3.14%)
12.07BMarket Cap
ACRO Biomedical Co., Ltd.
TPEX:6748
(Taipei Exchange)

Recent

price

185.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.75
0.29
0.59
0.61
0.58
0.96
0.72
0.62
- -
Revenue per Share
-1.62
-2.41
-1.63
-1.42
-1.27
-0.78
-1.01
-1.35
- -
Basic EPS, GAAP
-1.88
-2.15
-1.15
-1.43
-1.04
-1.33
-1.21
-1.03
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.78
2.03
2.89
3.41
7.28
11.1
10.13
15.51
14.96
Book Value per Share
2.76
1.98
2.82
3.2
7.12
10.96
10.03
15.41
14.88
Tangible Book Value per Share
23
25
31
36
48
53
61
61
71
Basic Weighted Avg Shares
17
7
18
22
28
51
44
38
- -
Sales/Revenue/Turnover
-262.72
-911.53
-310.35
-245.35
-227.17
-88.36
-150.35
-242.8
- -
Operating Margin (%)
13
16
13
10
9
11
13
17
- -
Depreciation Expense
-37
-61
-50
-51
-61
-41
-62
-83
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-216.13
-835.89
-277.37
-232.61
-220.33
-81.11
-140.37
-216.06
- -
Profit Margin (%)
122
80
139
91
338
593
511
986
943
Working Capital
- -
13
11
10
7
16
11
8
30
LT Debt
172
125
178
130
379
686
626
1,105
1,066
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-41.19
-32.92
-32.92
-23.94
-7.78
-9.46
-9.55
- -
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
4
2
4
LT Borrowings
- -
- -
- -
LT Finance Leases
9
8
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
71
71
Market Capitalization
2,092
4,700
12,071

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
481
1,006
959
Cash, Cash Equivalents & STI
453
978
917
Accounts Receivable, Net
2
3
13
Inventories
11
13
16
Total Current Liabilities
17
20
15
Payables & Accruals
- -
- -
- -
ST Debt
4
2
4
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
62.59%
76.36%
Free Cash Flow
- -
14.95%
-14.92%
Net Income, GAAP
- -
14.5%
33.13%
Sales/Revenue/Turnover
- -
21.11%
-13.51%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
44
2025
- -
- -
38
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.01
2025
- -
- -
-1.35
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
ACRO Biomedical Co., Ltd. develops and manufactures biomaterial medical devices specializing in human tissue engineering and regenerative medicine. The company’s core products include ABCcolla® Collagen Matrix for wound healing; ABCcolla® Bone Graft and Bone Matrix for orthopedic and dental bone repair promoting regeneration and vascularization; ABCcolla® Collagen Dermal Matrix (ADM) Scaffold for skin and soft tissue reconstruction; ABCcolla® Collagen Ophthalmic Matrix, a regenerative alternative to human corneal transplants; ACROTERM™ Scaffolds and Powders using porcine collagen for stem cell culture, tissue engineering, and 3D bioprinting; alongside wound care products and skin and eye care series. ACRO Biomedical applies proprietary supercritical carbon dioxide extraction technology to produce medical-grade collagen scaffolds, ensuring removal of cells and non-collagenous proteins while preserving the collagen structure for regenerative medical devices. Founded in Taiwan, where it is headquartered, ACRO Biomedical operates globally with regulatory approvals across multiple countries including Taiwan, Singapore, the Philippines, and markets in Australia and New Zealand via licensing agreements. The company serves medical segments such as orthopedics, dentistry, ophthalmology, cardiovascular, neural surgery, and aesthetic microsurgery. Recent major developments include gaining Taiwan Ministry of Health and Welfare approval for its Collagen Ophthalmic Matrix in 2025; securing Class III certification for multiple regenerative medical devices; expanded strategic partnerships including collaboration with Oculus Biomed Limited in Australia and a distribution alliance with DKSH; and a focus on advancing regenerative medicine technologies to address global tissue shortages. ACRO Biomedical also achieved significant growth recently, aiming for further expansion in regenerative medical device markets and published R&D advancements such as electro-optic collagen optimization and supercritical CO₂-processed biomaterials for wound healing and bone defect repair.